Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2008 1
2009 2
2010 1
2014 1
2016 1
2022 1
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.
Tefferi A. Tefferi A. J Cell Mol Med. 2009 Feb;13(2):215-37. doi: 10.1111/j.1582-4934.2008.00559.x. Epub 2008 Oct 23. J Cell Mol Med. 2009. PMID: 19175693 Free PMC article. Review.
FIP1L1-PDGFRA) or inter-chromosomal (e.g. ETV6-PDGFRB) gene fusions. BCR-ABL1 is associated with chronic myelogenous leukaemia (CML) and mutant PDGFR with an MPN phenotype characterized by eosinophilia and in addition, in case of FIP1L1-PDGFRA, bone marrow mastocyto …
FIP1L1-PDGFRA) or inter-chromosomal (e.g. ETV6-PDGFRB) gene fusions. BCR-ABL1 is associated with chronic myelogenous leukaemia …
Oncogenic signals as treatment targets in classic myeloproliferative neoplasms.
Tefferi A, Levine RL, Kantarjian H. Tefferi A, et al. Biol Blood Marrow Transplant. 2009 Jan;15(1 Suppl):114-9. doi: 10.1016/j.bbmt.2008.10.010. Biol Blood Marrow Transplant. 2009. PMID: 19147089 Free article. Review.
Therapeutically validated oncoproteins in myeloproliferative neoplasms (MPNs) include BCR-ABL in chronic myelogenous leukemia (CML) and a spectrum of PDGFRA/B mutant proteins that are products of intra- (eg, FIP1L1-PDGFRA) or interchromosomal (eg, ETV6-PDGFRB) gene …
Therapeutically validated oncoproteins in myeloproliferative neoplasms (MPNs) include BCR-ABL in chronic myelogenous leukemia (CML) and a sp …
Myeloid Neoplasms with t(5;12) and ETV6-ACSL6 Gene Fusion, Potential Mimickers of Myeloid Neoplasm with PDGFRB Rearrangement: Case Report with Imatinib Therapy and Review of the Literature.
De Luca-Johnson J, Ninfea JI, Pearson L, Conant J, Bryant R, Zakai NA, Tang ME. De Luca-Johnson J, et al. Case Rep Med. 2016;2016:8324791. doi: 10.1155/2016/8324791. Epub 2016 Sep 26. Case Rep Med. 2016. PMID: 27746819 Free PMC article.
ETV6-ACSL6 gene fusion is a rare abnormality that most often presents as a myeloproliferative-type disorder with prominent eosinophilia or basophilia. Review of the literature yielded a total of 11 previous cases. This gene fusion results in a t(5;12)(q31~33;p13) that mimi …
ETV6-ACSL6 gene fusion is a rare abnormality that most often presents as a myeloproliferative-type disorder with prominent eosinophilia or b …
Myeloid neoplasm with ETV6::ACSl6 fusion: landscape of molecular and clinical features.
Su Z, Liu X, Hu W, Yang J, Yin X, Hou F, Wang Y, Zhang J. Su Z, et al. Hematology. 2022 Dec;27(1):1010-1018. doi: 10.1080/16078454.2022.2117206. Hematology. 2022. PMID: 36069745 Free article. Review.
OBJECTIVES: Since the publication of the third edition, the WHO classification of tumors of hematopoietic and lymphoid disorders has introduced the disease entity of 'myeloid/lymphoid neoplasms with eosinophilia and PDGFRB rearrangement', in which the most common chromosomal abno …
OBJECTIVES: Since the publication of the third edition, the WHO classification of tumors of hematopoietic and lymphoid disorders has introdu …
Fusion genes in leukemia: an emerging network.
Bohlander SK. Bohlander SK. Cytogenet Cell Genet. 2000;91(1-4):52-6. doi: 10.1159/000056818. Cytogenet Cell Genet. 2000. PMID: 11173830 Review.
Not only does one find star-shaped topologies, with one gene forming fusions with several others (e.g. ETV6/PDGFRB, ETV6/JAK2, ETV6/ABL etc.), but also networks connecting several genes with more than one fusion partner (e.g. ...
Not only does one find star-shaped topologies, with one gene forming fusions with several others (e.g. ETV6/PDGFRB, ETV6/JAK2, …
[The hematological malignancies related to primary hypereosinophilia and their diagnostics].
Skonieczka K, Matiakowska K, Haus O. Skonieczka K, et al. Postepy Hig Med Dosw (Online). 2014 Dec 29;68:1530-7. doi: 10.5604/17322693.1134167. Postepy Hig Med Dosw (Online). 2014. PMID: 25834096 Free article. Review. Polish.
In differential diagnosis of hypereosinophilia, the analysis of characteristic gene mutations (e.g., cKIT) and gene fusions (e.g., ETV6-PDGFRB) is also applied, using molecular genetic methods....
In differential diagnosis of hypereosinophilia, the analysis of characteristic gene mutations (e.g., cKIT) and gene fusions (e.g., ETV6 …
[ABL1, SRC and other non-receptor protein tyrosine kinases as new targets for specific anticancer therapy].
Klener P, Klener P Jr. Klener P, et al. Klin Onkol. 2010;23(4):203-9. Klin Onkol. 2010. PMID: 20806817 Review. Czech.
Small molecule tyrosine kinase inhibitors interfere with these pathophysiological circuits by blocking the signalling cascades triggered by the aberrantly activated protein tyrosine kinases (e.g. BCR-ABL1, FIP1L1-PDGFRA or ETV6-PDGFRB).Tyrosine kinase inhibitors (im …
Small molecule tyrosine kinase inhibitors interfere with these pathophysiological circuits by blocking the signalling cascades triggered by …